Elacestrant: a new FDA-approved SERD for the treatment of breast cancer
| dc.contributor.author | Bhatia, Neha | |
| dc.contributor.author | Thareja, Suresh | |
| dc.date.accessioned | 2024-01-21T10:38:34Z | |
| dc.date.accessioned | 2024-08-13T12:05:31Z | |
| dc.date.available | 2024-01-21T10:38:34Z | |
| dc.date.available | 2024-08-13T12:05:31Z | |
| dc.date.issued | 2023-05-16T00:00:00 | |
| dc.description.abstract | Elacestrant (RAD-1901), a selective estrogen receptor degrader, was approved by USFDA on January 27, 2023, for the treatment of breast cancer. It has been developed by Menarini Group under the brand name Orserdu�. Elacestrant showed anticancer activity both in vitro and in vivo in ER+ HER2-positive breast cancer models. The present review delebrates the development stages of Elacestrant, with its medicinal chemistry, synthesis, mechanism of action, and pharmacokinetic studies. Clinical data and safety profile has also been discussed, including data from randomized trials. � 2023, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. | en_US |
| dc.identifier.doi | 10.1007/s12032-023-02045-2 | |
| dc.identifier.issn | 13570560 | |
| dc.identifier.uri | https://kr.cup.edu.in/handle/32116/3605 | |
| dc.identifier.url | https://link.springer.com/10.1007/s12032-023-02045-2 | |
| dc.language.iso | en_US | en_US |
| dc.publisher | Springer | en_US |
| dc.subject | Breast cancer | en_US |
| dc.subject | Elacestrant | en_US |
| dc.subject | Estrogen | en_US |
| dc.subject | Orserdu | en_US |
| dc.subject | SERD | en_US |
| dc.title | Elacestrant: a new FDA-approved SERD for the treatment of breast cancer | en_US |
| dc.title.journal | Medical Oncology | en_US |
| dc.type | Review | en_US |
| dc.type.accesstype | Closed Access | en_US |